Introduction {#sec1}
============

In March 2020, the World Health Organization declared COVID-19 a global pandemic. Worldwide, almost 2 million people have been infected with this virus and more than 120,000 deaths have been reported.[@bib1] In anticipation of the surge of COVID-19 cases in the United States, the Surgeon General of the United States advised hospitals to cancel all elective procedures.[@bib2] The American College of Surgeons and the 4 national gastroenterology organizations similarly recommended that elective procedures should be rescheduled to mitigate the spread of COVID-19 and preserve personal protective equipment.[@bib3] ^,^ [@bib4] Subsequently, the American Gastroenterological Association (AGA) issued recommendations suggesting that only time-sensitive GI endoscopy procedures should be performed.[@bib5] A joint GI society statement and recommendations from a group of New York physicians were also published, providing limited advice regarding which procedures should be performed during the pandemic.[@bib6] ^,^ [@bib7]

Despite these recommendations, there continues to be ambiguity among practicing gastroenterologists regarding which endoscopic procedures should be performed during the COVID-19 pandemic, and which ones could be safely deferred.[@bib8] To provide more specific guidance on triaging endoscopic procedures, we used a modified Delphi methodology to attain expert consensus regarding procedural timing for advanced endoscopic procedures. The Delphi method is a validated and structured technique to obtain expert consensus, and it is particularly well suited for the present situation where there is limited outcome data, and guidance for procedural timing is urgently needed.[@bib9] ^,^ [@bib10] Conducting new studies to assess outcomes related to delaying procedures amidst the ongoing pandemic is impractical. The Delphi method allows for timely formulation of expert consensus in a rigorous and systematic manner. We also recognized that delaying procedures not only has clinical implications but also moral and ethical ones. We therefore designed our study to emphasize patient-important outcomes while considering procedural timing.

Methods {#sec2}
=======

Our study overview is shown in [Figure 1](#fig1){ref-type="fig"} and was as follows: our initial step was to achieve consensus on the patient-important outcome(s) for each advanced endoscopy indication. Experts were then asked to determine the timing of the advanced endoscopy procedure for each indication while strongly prioritizing patient-important outcomes in their decision making. Detailed study steps were as follows:(1)Selection of expert panel. An expert panel of 14 gastroenterologists was invited such that diversity was achieved in geography, practice location (academic, private practice, and Veterans Administration), and practice type (general gastroenterology and advanced endoscopy).(2)Selecting advanced endoscopy procedure indications (survey no. 1). American Society for Gastrointestinal Endoscopy (ASGE) guidelines on the "Appropriate Use of GI Endoscopy" were reviewed, and advanced endoscopy procedure indications were identified.[@bib11] Advanced endoscopy procedures were defined as those that required training in addition to what is typically provided during a general gastroenterology fellowship. These procedures included but were not limited to ERCP and EUS. Indications identified in the ASGE guideline were then adapted for inclusion in this survey.(3)An affinity chart was created using patient-important outcomes extracted from several clinical studies.[@bib12] ^,^ [@bib13] Using a grouping process, we identified 4 major groups of patient-important outcomes that were relevant to our study: (1) avoidance of death/prolongation of life, (2) avoidance of cancer/avoidance of cancer progression, (3) avoidance of major surgery and/or hospitalization, and (4) improvement or palliation of symptoms.(4)Panelists were asked to choose up to 2 critical patient-important outcomes from the categories mentioned in point (3) for each indication (survey no. 1). Panelists were also allowed to add other patient-important outcomes.(5)Panelists were also asked to suggest additional indications for commonly performed advanced endoscopy procedures that were not already listed in survey no. 1. Figure 1Study overview.

The consensus threshold was set at \>51% and responses were kept anonymous.(6)Procedure indications for which patient-important outcomes failed to reach the consensus threshold, and new procedure indications suggested by panelists were discussed in video conference call no. 1.(7)Discussion followed by voting for each indication was undertaken in keeping with the Delphi technique (video conference call no. 1). If despite 3 rounds of discussion and voting, consensus could not be reached, attempts at further consensus were abandoned.(8)A panel of experts from our previous study on triaging general endoscopy procedures had achieved consensus that procedure timing should be categorized into the following blocks: (1) time-sensitive emergent (schedule within 1 week), (2) time-sensitive urgent (schedule within 1 to 8 weeks), (3) non-time sensitive (defer for \>8 weeks and then reassess the timing). We used the same categorization for our present study.(9)Panelists were asked to select one of 3 timing categories described in point (8) for each procedure indication (survey no. 2). The consensus threshold was set at \>66.7% and responses were kept anonymous.(10)Procedure indications that failed to reach the consensus threshold were identified. Video conference call no. 2 took place, and rules similar to conference call no. 1 were applied.

Results {#sec3}
=======

Expert panel {#sec3.1}
------------

The expert panel comprised 14 gastroenterologists, and all those who were invited to participate in the survey agreed at the first invitation. There were 12 advanced endoscopists, 1 general gastroenterologist, and 1 advanced endoscopy fellow. The average years in practice was 12 years (range, 1-27 years). Thirteen of the panelists worked in academic teaching hospitals, 1 at a Veterans Administration hospital, and 1 in private/community practice. Ten of the panelists only performed endoscopy in hospital-based endoscopy units, whereas 4 performed endoscopy in both ambulatory surgical centers and hospital-based endoscopy units. Seven panelists were from northeastern, 2 from western, 3 from midwestern, and 2 from southern United States. All panelists were currently performing endoscopy at their institutions. The average proportion of procedures being performed now compared with before the pandemic was 16.4% (range, 5%-30%).

Consensus on patient-important outcomes {#sec3.2}
---------------------------------------

Thirty-seven advanced endoscopy indications were adapted from the ASGE "Appropriate Use of GI Endoscopy" guidelines.[@bib11] During survey no. 1, panelists added 4 indications. These were all related to EGD procedures and are shown as indications 9 to 12 in [Table 1](#tbl1){ref-type="table"} . This resulted in a total of 41 advanced endoscopy indications. We defined the consensus threshold a priori to be 51%. Consensus on patient-important outcome was achieved at survey no. 1 for 35 of 41 indications. Consensus on the remaining 6 indications was achieved during discussion and voting during video conference call no. 1.Table 1Indications related to upper endoscopyProcedural indicationCritical patient-important outcome(s)Consensus time intervalConsensus reached (%)1Familial adenomatous polyposis syndrome for surveillance of ampullary and duodenal malignancyAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing1002Esophageal cancer and dysphagia, for esophageal stent placementImprovement or palliation of symptomsWithin 1 week69.23Symptomatic malignant gastric outlet obstruction, for duodenal stent placementImprovement or palliation of symptomsWithin 1 week84.64Achalasia with dysphagia, for endoscopic treatment (able to tolerate pureed diet and thick liquids)[∗](#tbl1fnlowast){ref-type="table-fn"}Improvement or palliation of symptomsDefer \>8 weeks, and reassess timing1005Barrett's esophagus with low-grade dysplasia, for radiofrequency ablationAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing1006Barrett's esophagus with flat high-grade dysplasia, for radiofrequency ablation[∗](#tbl1fnlowast){ref-type="table-fn"} ^,^ [†](#tbl1fndagger){ref-type="table-fn"}Avoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing1007Barrett's esophagus with nodular high-grade dysplasia (confirmed by expert pathologist), for EMR[∗](#tbl1fnlowast){ref-type="table-fn"} ^,^ [†](#tbl1fndagger){ref-type="table-fn"}Avoidance of cancer/cancer progression; avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing758Patients with upper GI perforations or acute suture line dehiscence, for endoscopic closureAvoidance of major surgery and/or hospitalizationWithin 1 week1009Esophageal stricture with dysphagia, for dilation (able to ingest thick liquids and pureed food)Improvement or palliation of symptomsWithin 1-8 weeks69.210EGD in patients with subacute anemia from bleeding gastric polyp/s, for polypectomy[∗](#tbl1fnlowast){ref-type="table-fn"}Avoidance of major surgery and/or hospitalizationWithin 1-8 weeks7511Asymptomatic patients with precancerous gastric polyp/s, for polypectomy[∗](#tbl1fnlowast){ref-type="table-fn"}Avoidance of cancer/cancer progression; avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing100[^2][^3]

Consensus on procedural timing {#sec3.3}
------------------------------

Survey no. 2 was considered the first round of voting, and the consensus threshold of 66.7% defined a priori was achieved for 23 of 41 indications. For the remaining 18 indications, consensus was achieved for 13 indications during the second round of voting. The expert panel voted to modify the remaining 5 indications. These indications are delineated in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"} . After these modifications, a third round of voting was conducted, and consensus was achieved for 4 of the 5 indications. In aggregate, consensus on procedural timing for 40 of 41 indications was achieved. The experts achieved 100% consensus for 12 of 41 indications, 75% to 99% consensus for 20 of 41 indications, and 67% to 74% consensus for 8 of 41 indications ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}). The only indication for which consensus could not be achieved despite modification and 3 voting rounds was "Incidentally found pancreatic duct dilation \>6 mm and common bile duct dilation \>10 mm on CT scan or magnetic resonance imaging (with normal results for liver function tests)."Table 2Indications related to colonoscopyProcedural indicationCritical patient-important outcome(s)Consensus time intervalConsensus reached (%)12A \>2 cm colon polyp with biopsies showing adenoma, for EMRAvoidance of cancer/cancer progression; avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing84.613A \>2 cm colon polyp with biopsies showing adenoma with high-grade dysplasia, for EMR[∗](#tbl2fnlowast){ref-type="table-fn"} ^,^ [†](#tbl2fndagger){ref-type="table-fn"} ^,^ [‡](#tbl2fnDagger){ref-type="table-fn"}Avoidance of cancer/cancer progression; avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing8214Bowel obstruction from obstructing colon mass, for colon stent placementImprovement or palliation of symptoms; avoidance of major surgery and/or hospitalizationWithin 1 week100[^4][^5][^6]Table 3Indications related to ERCPProcedural indicationCritical patient-important outcome(s)Consensus time intervalConsensus reached (%)15Painless jaundice with suspected biliary obstruction[∗](#tbl3fnlowast){ref-type="table-fn"}Improvement/palliation of symptomsWithin 1-8 weeks9116Jaundice with suspected biliary obstruction, with abdominal pain (no cholangitis suspected)Improvement/palliation of symptoms; avoidance of major surgery/hospitalizationWithin 1 week69.217Jaundice with suspected cholangitisAvoidance of death/prolongation of lifeWithin 1 week10018No jaundice, but abnormal liver function test results and abdominal pain, with known/suspected choledocholithiasis[∗](#tbl3fnlowast){ref-type="table-fn"} ^,^Avoidance of major surgery and/or hospitalizationWithin 1 week7019Normal liver function test results and incidental finding of choledocholithiasis on imaging studies[∗](#tbl3fnlowast){ref-type="table-fn"} ^,^ [†](#tbl3fndagger){ref-type="table-fn"} ^,^ [‡](#tbl3fnDagger){ref-type="table-fn"}Avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing8320Asymptomatic patient with pancreatic stent, for ERCP for stent removalAvoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing7521Asymptomatic patients with plastic biliary stent for \>3 months, for stent removal[∗](#tbl3fnlowast){ref-type="table-fn"}Avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing6722Postsurgical bile leakAvoidance of major surgery and/or hospitalizationWithin 1 week10023Patients with ampullary adenoma, for ampullectomyAvoidance of cancer/avoidance of cancer progression; avoidance of major surgery and /or hospitalizationDefer \>8 weeks, and reassess timing84.624Patients with ampullary adenoma with high-grade dysplasia, for ampullectomy[∗](#tbl3fnlowast){ref-type="table-fn"}Avoidance of cancer/avoidance of cancer progression; avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing6725Patients with chronic pancreatitis with obstructing pancreatic duct stones and abdominal pain, for stone management[∗](#tbl3fnlowast){ref-type="table-fn"}Avoidance of major surgery and/or hospitalization and Improvement or palliation of symptomsDefer \>8 weeks, and reassess timing9226Patient post liver transplant with unexplained increase in the results of liver function test or bilirubin level, anastomotic stricture suspected[∗](#tbl3fnlowast){ref-type="table-fn"}Avoidance of major surgery and/or hospitalizationWithin 1-8 weeks75[^7][^8][^9]Table 4Indications related to EUS and enteroscopyProcedural indicationCritical patient-important outcome(s)Consensus time intervalConsensus reached (%)27EUS for staging esophageal, gastric or rectal cancerAvoidance of cancer/cancer progressionWithin 1-8 weeks69.328A \<2 cm subepithelial esophageal, gastric or duodenal massAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing10029A \>2 cm subepithelial esophageal, gastric, or duodenal massAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing76.930Malignant-appearing solid mass in the pancreas on CT or magnetic resonance imaging[∗](#tbl4fnlowast){ref-type="table-fn"}Avoidance of cancer/cancer progressionWithin 1-8 weeks8331Incidentally discovered \>2 cm cystic lesion in pancreas on CT or magnetic resonance imagingAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing84.632Incidentally found main pancreatic duct dilation \>6 mm on CT scan or magnetic resonance imaging[∗](#tbl4fnlowast){ref-type="table-fn"}Avoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing6733Incidentally found common bile duct dilation \>10 mm on CT scan or magnetic resonance imagingAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing84.634Incidentally found pancreatic duct dilation \>6 mm and common bile duct dilation \>10 mm on CT scan or magnetic resonance imaging (normal results for liver function tests)[∗](#tbl4fnlowast){ref-type="table-fn"} ^,^ [†](#tbl4fndagger){ref-type="table-fn"}Avoidance of cancer/cancer progressionNo consensus was achieved35Pancreatic cancer awaiting fiducial placement to start radiation treatment[∗](#tbl4fnlowast){ref-type="table-fn"}Avoidance of cancer/cancer progressionWithin 1-8 weeks9236Symptomatic pseudocyst or walled-off necrosis (infection not suspected), for EUS guided drainageImprovement/ palliation of symptoms; avoidance of major surgery/hospitalizationWithin 1-8 weeks76.937Symptomatic pseudocyst or walled-off necrosis (infected suspected), for EUS guided drainageAvoidance of death/prolongation of life; avoidance of major surgery/hospitalizationWithin 1 week10038Intractable pancreatic cancer-related abdominal pain, for celiac plexus neurolysis[∗](#tbl4fnlowast){ref-type="table-fn"}Improvement or palliation of symptomsWithin 1-8 weeks7539Idiopathic acute recurrent pancreatitisAvoidance of major surgery/hospitalizationDefer \>8 weeks, and reassess timing84.640High risk for pancreatic cancer undergoing pancreatic cancer screeningAvoidance of cancer/cancer progressionDefer \>8 weeks, and reassess timing10041Patients with subacute anemia and known small-bowel arteriovenous malformations, for treatment of arteriovenous malformations[∗](#tbl4fnlowast){ref-type="table-fn"}Avoidance of major surgery and/or hospitalizationDefer \>8 weeks, and reassess timing83[^10][^11]

Discussion {#sec4}
==========

We used a modified Delphi method to achieve consensus among experts in categorizing 40 of 41 advanced endoscopy procedure indications into 1 of 3 timing categories: (1) time-sensitive emergent (schedule within 1 week), (2) time-sensitive urgent (schedule within 1 to 8 weeks), or (3) non-time sensitive (defer for \>8 weeks and then reassess the timing). We placed patient priorities at the center of this decision-making process by prioritizing patient-important outcomes. This study provides a decision-making framework by which endoscopists may determine scheduling timing for endoscopic procedures as they start to reopen their endoscopy suites.

Several guidelines have been published on procedural timing during the COVID-19 pandemic.[@bib4] ^,^ [@bib5] ^,^ [@bib7] An expert panel previously constituted by our study group to triage general endoscopic procedures had failed to reach consensus on any of these pre-existing categorizations (unpublished data). Instead, by consensus, the expert panel modified the AGA recommendations into 3 time categories for procedural timing: (1) time-sensitive emergent (schedule within 1 week), (2) time-sensitive urgent (schedule within 1 to 8 weeks), and (3) non-time sensitive (defer for \>8 weeks and then reassess timing).[@bib5] The panel felt that the AGA "time-sensitive category" (schedule within 0 to 8 weeks) was too broad and did not adequately differentiate between emergent procedures, such as acute cholangitis, and urgent procedures that could be delayed a few weeks, such as cancer staging. We chose to adopt these three-tier timing categories for our present study. In our previous study, we also prioritized patient-important outcomes during decision making. Patient-important outcomes are defined as characteristics or variables that reflect how a patient feels, functions, or survives.[@bib14] ^,^ [@bib15] These are outcomes that patients' value and are related to death and quality of life (morbidity, pain, function). This structure was relevant for our present study, because it placed patient preferences at the center of decision making, avoided a multistep decision tree, and could be adapted to iterative improvements using the Delphi technique.

Some indications required significant discussion to achieve consensus.

Indications 5 to 7 {#sec4.1}
------------------

For radiofrequency ablation for low- and high-grade dysplasia, 100% consensus was achieved that ablation could be deferred for \>8 weeks given the low short-term risk of disease progression, estimated at 1.7%/year for progression of low-grade dysplasia to either high-grade dysplasia or cancer, and 7%/year for malignant transformation of high-grade dysplasia.[@bib16] However, for EMR to treat nodular high-grade dysplasia (confirmed by expert pathologist review), a lower consensus of 75% was achieved on concerns regarding the accuracy of biopsies in detecting the most advanced pathology present, given data indicating that EMR can often upstage a biopsy diagnosis of high-grade dysplasia.[@bib17] ^,^ [@bib18]

Indications 12 and 13 {#sec4.2}
---------------------

Deferring EMR of large (≥20 mm) colorectal polyps for 8 weeks may increase the risk of transition to cancer or progression of unrecognized cancer to more invasive cancer. The risk of covert prevalent cancer in such polyps ranges from 3% to 7%,[@bib19], [@bib20], [@bib21] with a lower risk where biopsy specimens do not indicate cancer. Although covert cancer may be missed due to sampling error, the likelihood of progression to an unresectable stage within 8 weeks is unlikely. Moreover, with EMR, the risk of adverse events requiring hospital admission is 5% to 10%,[@bib22] which could put the patient and others at increased risk for COVID-19 exposure. In addition, polyp characteristics maybe helpful in characterizing the risk of prevalent cancer, including location in the rectum, nongranular appearance, and very large size,[@bib21] and should be considered when making individual recommendations.

Indications 15 and 30 to 34 {#sec4.3}
---------------------------

Early diagnosis is essential in improving survival in patients with a high suspicion of pancreaticobiliary malignancy,[@bib23] including patients with painless obstructive jaundice, or with cross-sectional imaging demonstrating a malignant-appearing solid mass in the pancreas. In the absence of symptoms, consensus was reached that endoscopic intervention should be performed in 1 to 8 weeks. Main pancreatic duct dilation \>6 mm may precede the diagnosis of pancreatic cancer by several months.[@bib23], [@bib24], [@bib25] In the absence of additional imaging abnormalities, such as a stricture, the consensus was that evaluation with endoscopic ultrasonography could be deferred by 8 weeks, then reassessed. For isolated biliary dilation without symptoms or biochemical derangements, the likelihood of significant biliary pathology is low,[@bib26], [@bib27], [@bib28] and the consensus was that evaluation could be deferred by 8 weeks, then reassessed When this finding co-existed with pancreatic duct dilation \>6 mm, no consensus was reached for procedural timing.

Indications 16 to 19 {#sec4.4}
--------------------

Although some studies have shown that endoscopic stone removal in asymptomatic patients has little effect in preventing biliary adverse events,[@bib29] a large Swedish registry cohort analysis suggested that stone removal resulted in improved outcomes.[@bib30] Although ERCP is usually undertaken in patients with asymptomatic choledocholithiasis, early ERCP is not warranted because the short-term risk of biliary adverse events is low,[@bib29] and the consensus was to defer ERCP for \>8 weeks, then reassess. There was broad consensus that symptomatic patients with known/suspected choledocholithiasis required ERCP within 1 week and that urgent ERCP was warranted in patients with acute cholangitis, because this is associated with lower in-hospital mortality, 30-day mortality, length of hospital stay, and organ failure.[@bib31] ^,^ [@bib32]

Indications 20 and 21 {#sec4.5}
---------------------

The risk of permanent duct changes and pancreatitis is low with small-caliber pancreatic stents, and given the high spontaneous migration rate (\>85% by 100 days), deferring ERPC for \>8 weeks was deemed appropriate.[@bib33] In young patients, women, those with a history of recurrent acute pancreatitis, small pancreatic duct diameter, or 5F stent placement, removal in \<8 weeks may be appropriate.[@bib34] For patients with biliary stent in situ for 3 months, there was agreement among only 67% of panelists to defer stent exchange for \>8 weeks. Most panelists felt that routine stent changes could be deferred during this pandemic as long as close clinical follow-up of patients was undertaken, and an individualized approach was undertaken to balance the risk of stent occlusion with that of exposure to COVID-19. Thus, some patients are at relatively low risk for biliary stent occlusion; for example, stent placement after incomplete clearance of bile duct stones, or treatment of postoperative bile leak, or those with multiple stents in place for stricture management.[@bib35] In contrast, patients with malignant hilar strictures or distal biliary strictures may be at a higher risk of stent occlusion.[@bib36] ^,^ [@bib37]

Indication 27 {#sec4.6}
-------------

For EUS staging of GI cancer, there was 69% consensus that procedures should occur within 1 to 8 weeks. Differing opinions over timing centered around 2 issues: (1) unpredictability regarding the possibility of clinically relevant tumor progression over an 8-week time period, owing to significant variability of tumor doubling times and (2) patient anxiety surrounding a new diagnosis of malignancy and the importance of establishing a treatment plan.[@bib38]

Some aspects and limitations of our study warrant further discussion. First, our recommendations are based on expert opinion. The decision to perform endoscopy during the COVID-19 pandemic needs to balance the risks associated with delaying the procedure with the risk of viral exposure to patients and health care providers. Literature on outcomes when procedures are delayed, especially for short duration of up to 8 weeks, and on the likelihood of acquiring COVID-19 infection during endoscopy, are extremely limited. Furthermore, scheduling timing decisions also needs to take into consideration factors, such as saving personal protective equipment in a time of dire shortage and avoiding diversion of hospital resources away from the direct care of patients infected with COVID-19. Complex nonlinear decisions that require subjective judgment are often unsuitable for traditional methods of guideline development. However, the Delphi method is well suited for such situations because it is a validated methodology that provides a framework whereby conflicting values and differing opinions can be systematically incorporated to achieve consensus.[@bib39] Anonymity is an important aspect of the Delphi method and reduces the likelihood of personality conflicts and status relations and helps preserve constructive group dynamics. In our study, results of the written survey and voting during video conferences were anonymous. However, panelists were able to see and hear each other during the video conferences, and this may have potentially biased their responses. Second, in the absence of a universally accept threshold, we chose an arbitrary value of 66.7% agreement to declare expert consensus when determining procedural timing. Not all recommendations achieved the same level of expert consensus, and this should also be taken into consideration when using an individual recommendation. Third, we fully recognize that in addition to procedural indications, factors including severity of symptoms and patient co-morbidities should be considered when determining procedural timing. We hope that our recommendations will serve as a starting point for such difficult decision making, and that endoscopists will adapt these on a case-by-case basis to reach their final recommendation. We are entering a new phase of the COVID-19 pandemic where there is even more heterogeneity in the prevalence of infection across the country. Our system of categorizing procedures into broad time periods allows endoscopists the flexibility to take these local circumstances as well as local resource availability into consideration.

In conclusion, using a structured decision framework that prioritized patient-important outcomes, we were successful in achieving consensus on procedural timing for 40 of 41 common indications for advanced endoscopy procedures. We chose to classify indications within a 3-tier system that provided specific guidance while allowing gastroenterologists the additional flexibility in scheduling procedures. We believe it will take many months before endoscopy capacity returns close to prepandemic levels. It is our hope that these guidelines will serve as a useful instrument for endoscopists in planning their strategy as they reopen and ramp up endoscopy at their institutions.

If you would like to chat with an author of this article, you may contact Dr Sawhney at <msawhney@bidmc.harvard.edu>.
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